Kenya - English - Pharmacy and Poisons Board

bliss gvs pharma limited 102, hyde park, saki vihar road, andheri (east) - - formoterol fumarate and budesonide inhalation - pressurised inhalation - each actuation delivers: formoterol fumarate… - formoterol and budesonide

Kenya - English - Pharmacy and Poisons Board

bliss gvs pharma ltd 102, hyde park, saki-vihar road, andheri (east), - formoterol fumarate and budesonide inhalation - pressurised inhalation - each actuation delivers: formoterol fumarate… - formoterol and budesonide

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - formoterol fumarate 12ug - powder filled inhalation capsule - 12 mcg - active: formoterol fumarate 12ug excipient: gelatin ink lactose monohydrate - foradil is indicated for the treatment of bronchoconstriction in adults and children six years of age and over with asthma as an add-on to inhaled corticosteroid (ics) treatment. in the management of asthma, foradil should be used only as an adjunct to corticosteroids. foradil should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - formoterol fumarate 12ug;   - powder for inhalation - 12 mcg/dose - active: formoterol fumarate 12ug   excipient: lactose monohydrate

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - formoterol fumarate 4.5ug (/dose for the m3 device. equivalent to 6 µg/dose of the m2 device.);   - powder for inhalation - 6 mcg/dose - active: formoterol fumarate 4.5ug (/dose for the m3 device. equivalent to 6 µg/dose of the m2 device.)   excipient: lactose monohydrate - oxis turbuhaler is indicated as add on therapy to maintenance treatment with inhaled corticosteroids for the treatment of broncho-obstructive symptoms and prevention of exercise-induced symptoms in adults and children six years of age and over with asthma when adequate treatment with corticosteroids is not sufficient. oxis turbuhaler should not be used in the treatment of acute asthmatic symptoms or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - formoterol fumatrate dihydrate; budesonide - inhalation powder - 400/12 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - formoterol fumatrate dihydrate; budesonide - inhalation powder - 200 µg/6 µg/inhalation - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - formoterol fumatrate dihydrate; budesonide - inhalation powder - 200 µg/6 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - formoterol fumarate dihydrate; budesonide - inhalation powder - 400 µg /12 µg/inhalation - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide - adrenergics and other drugs for obstructive airway diseases. - it is indicated: in adults and adolescents aged 12 to 17 years for the regular treatment of asthma where use of a combination is appropriate; in adults, aged 18 years and older, for the symptomatic treatment of patients with severe copd and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators